Format

Send to

Choose Destination
Nat Med. 2015 Apr;21(4):395-400. doi: 10.1038/nm.3824. Epub 2015 Mar 23.

Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy.

Author information

1
Graduate School of Medical Science and Engineering, KAIST, Daejeon, Korea.
2
1] Division of Pediatric Neurology, Department of Pediatrics, Pediatric Epilepsy Clinics, Severance Children's Hospital, Seoul, Korea. [2] Epilepsy Research Institute, Yonsei University College of Medicine, Seoul, Korea.
3
Department of Pathology, Brain Korea 21 project for medical science, Yonsei University College of Medicine, Seoul, Korea.
4
Department of Biological Sciences, KAIST, Daejeon, Korea.
5
1] Epilepsy Research Institute, Yonsei University College of Medicine, Seoul, Korea. [2] Department of Neurosurgery, Pediatric Epilepsy Clinics, Brain Korea 21 project for medical science, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea.
6
Korea Basic Science Institute, Chuncheon Center, Chuncheon-si, Gangwon-do, Korea.
7
Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
8
Macrogen Bioinformatics Center, Macrogen, Gasan-dong, Geumcheon-gu, Seoul, Korea.

Abstract

Focal cortical dysplasia type II (FCDII) is a sporadic developmental malformation of the cerebral cortex characterized by dysmorphic neurons, dyslamination and medically refractory epilepsy. It has been hypothesized that FCD is caused by somatic mutations in affected regions. Here, we used deep whole-exome sequencing (read depth, 412-668×) validated by site-specific amplicon sequencing (100-347,499×) in paired brain-blood DNA from four subjects with FCDII and uncovered a de novo brain somatic mutation, mechanistic target of rapamycin (MTOR) c.7280T>C (p.Leu2427Pro) in two subjects. Deep sequencing of the MTOR gene in an additional 73 subjects with FCDII using hybrid capture and PCR amplicon sequencing identified eight different somatic missense mutations found in multiple brain tissue samples of ten subjects. The identified mutations accounted for 15.6% of all subjects with FCDII studied (12 of 77). The identified mutations induced the hyperactivation of mTOR kinase. Focal cortical expression of mutant MTOR by in utero electroporation in mice was sufficient to disrupt neuronal migration and cause spontaneous seizures and cytomegalic neurons. Inhibition of mTOR with rapamycin suppressed cytomegalic neurons and epileptic seizures. This study provides, to our knowledge, the first evidence that brain somatic activating mutations in MTOR cause FCD and identifies mTOR as a treatment target for intractable epilepsy in FCD.

PMID:
25799227
DOI:
10.1038/nm.3824
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center